Skip to main navigation Skip to search Skip to main content

Systematic functional validation of IKAROS variants from patients and laboratory-generated mutations

  • Hye Sun Kuehn
  • , Agustin A. Gil Silva
  • , Natchanun Klangkalya
  • , Ana Esteve-Sole
  • , Shubham Goel
  • , Julie E. Niemela
  • , Jennifer L. Stoddard
  • , Hey Chong
  • , Kelli Williams
  • , Winnie Ip
  • , Mario Framil Seoane
  • , Sathish Kumar Loganathan
  • , Ariharan Anantharachagan
  • , Ana García-Soidán
  • , Serena Shaffren
  • , Constance Bindernagel
  • , Philip Mendez
  • , Rahim Z. Miller
  • , Hassan Abolhassani
  • , David P. Hoytema van Konijnenburg
  • Ashley V. Geerlinks, Diana Cabanillas, Evelien Zonneveld-Huijssoon, Abraham Rutgers, Stuart Tangye, Cindy Ma, Alice Grey, Patrick O'Young, Juan Carlos Aldave Becerra, Jonathan J. Lyons, Andrew A. White, Michael Claiborne, Mohammad Ali Doroudchi, Brian D. Modena, Joshua D. Milner, Xavier Solanich, João Farela Neves, Craig D. Platt, Lennart Hammarström, John M. Routes, James Verbsky, Manish J. Butte, Harry Lesmana, William J.H. Griffiths, Dinakantha Kumararatne, Fabian Hauck, Luis M. Allende, Carlos Rodríguez-Gallego, Reem Elfeky, Tamar Rubin, Kaan Boztug, Thomas A. Fleisher, Sergio D. Rosenzweig
  • National Institutes of Health
  • Children's Hospital of Pittsburgh
  • Medical University of South Carolina
  • University College London Great Ormond Street Institute of Child Health
  • Hospital Clínic de Barcelona
  • Christian Medical College, Vellore
  • Lancashire Teaching Hospitals NHS Foundation Trust
  • Hospital Universitario Dr Negrín
  • All Children's Hospital St. Petersburg
  • University of South Florida
  • Karolinska Institutet
  • Research Center for Immunodeficiencies
  • Children's Hospital
  • University of Western Ontario
  • Hospital Interzonal Especializado en Pediatría “Sor María Ludovica”
  • University of Groningen
  • Garvan Institute of Medical Research
  • UNSW Sydney
  • Clinical Immunogenomics Research Consortium Australasia
  • Royal Prince Alfred Hospital
  • Westmead Hospital
  • Hospital Nacionale Edgardo Rebagliati
  • Division of Infectious Diseases, Department of Medicine, University of California, San Diego
  • VA San Diego Healthcare System
  • Scripps Clinic
  • Modena Health
  • Columbia University Medical Center
  • Hospital Universitari de Bellvitge
  • Hospital Dona Estefânia
  • Universidade Nova de Lisboa
  • Medical College of Wisconsin
  • VA Greater Los Angeles Healthcare System and David Geffen School of Medicine at the University of California
  • Case Western Reserve University
  • Addenbrooke's Hospital
  • Ludwig-Maximilians-University of Munich
  • Hospital Universitario 12 de Octubre
  • University of Las Palmas de Gran Canaria
  • University of Fernando Pessoa Canarias
  • Instituto de Salud Carlos III
  • Royal Free Hospital
  • University of Manitoba
  • St. Anna Children's Cancer Research Institute
  • University Clinic

Research output: Contribution to journal › Article › peer-review

Abstract

The transcription factor IKAROS plays an important role in lymphocyte development, differentiation, and as a tumor suppressor. To date, >70 IKAROS germ line heterozygous variants have been reported in patients with primary immunodeficiency (PID)/inborn errors of immunity (IEI) and leukemia, and this number continues to grow. Germ line IKAROS loss- and gain-of-function mutations have been linked to immunodeficiency, immune dysregulation, and hematologic malignancies, with a broad spectrum of clinical manifestations. Routine next-generation sequencing approaches in patients with PID/IEI have facilitated the identification of IKAROS variants, including several cases with variants of uncertain significance (VUS). To determine the VUS’ functional behavior, we systematically generated constructs recapitulating those changes and tested IKAROS functions in vitro. We also conducted an in-depth examination of the C-terminal dimerization domain using alanine-scanning mutagenesis to identify amino acids critical for dimerization and other functions. This work provides a comprehensive description of the biologic impact of 81 previously unreported and/or untested IKAROS variants, including 33 patient-detected germ line VUS and 48 laboratory-generated mutations in the dimerization domain. Among them, 15 of the patient-detected variants, primarily mapping to IKAROS DNA-binding or dimerization domains, and at least 21 of the laboratory-generated mutations, impaired IKAROS function and could explain or result in human disease. VUS located in between IKAROS DNA binding and dimerization domains were less likely to be functionally deleterious. Of note, both positive and negative functional data herein generated can be relevant for patients carrying these IKAROS variants, helping to establish a diagnosis and guide treatment decisions.

Original languageEnglish
Pages (from-to)1522-1536
Number of pages15
JournalBlood Advances
Volume10
Issue number5
DOIs
Publication statusPublished - 10 Mar 2026

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Systematic functional validation of IKAROS variants from patients and laboratory-generated mutations'. Together they form a unique fingerprint.

Cite this